<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02580344</url>
  </required_header>
  <id_info>
    <org_study_id>IUD_Ibuprofen</org_study_id>
    <nct_id>NCT02580344</nct_id>
  </id_info>
  <brief_title>The Effect of Ibuprofen on Intrauterine Contraceptive Device Associated Uterine Bleeding</brief_title>
  <official_title>Action of Ibuprofen on IUD-associated Heavy Menstrual Bleeding</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The Copper intrauterine device is the most common method of reversible contraception&#xD;
      worldwide. Abnormal uterine bleeding and pain are the most common medical indications for the&#xD;
      discontinuation of the intrauterine device.&#xD;
&#xD;
      Excessive prostaglandin release in the endometrial cavity appears to play an important role&#xD;
      in both bleeding and pain related to copper intrauterine devices.There are many types of&#xD;
      prostaglandin metabolites that present in the endometrium one of them is prostacyclin which&#xD;
      causes vasodilatation and inhibits platelet aggregation. Another one is thromboxane which has&#xD;
      two types; A2 which is active and rapidly converted into B2, which is inactive. Thromboxane&#xD;
      causes vasoconstriction and blood clotting.&#xD;
&#xD;
      Non-steroidal anti-inflammatory drugs (NSAIDs) are prostaglandin synthetase inhibitors acting&#xD;
      by decreasing production of endometrial prostaglandins; they can improve both heavy uterine&#xD;
      bleeding and pain. Since its discovery; several drugs in NSAIDs class have been used to treat&#xD;
      heavy uterine bleeding and pain associated with copper intrauterine device use such as&#xD;
      mefenamic acid, ibuprofen and naproxen.&#xD;
&#xD;
      The most recent systematic review found NSAIDs is the most widely studied drugs for reduction&#xD;
      of the menstrual blood and pain associated with copper intrauterine device. The Cochrane&#xD;
      Review also found that NSAIDs are the most effective treatment to reduce the bleeding with&#xD;
      copper intrauterine device use.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 2015</start_date>
  <completion_date type="Actual">November 2016</completion_date>
  <primary_completion_date type="Actual">September 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of bleeding days per month</measure>
    <time_frame>3 months</time_frame>
    <description>by menstrual diary</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Uterine Doppler indices</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">128</enrollment>
  <condition>Contraception</condition>
  <arm_group>
    <arm_group_label>Ibuprofen</arm_group_label>
    <arm_group_type>Other</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibuprofen</intervention_name>
    <description>The women will receive 400mg ibuprofen 3 times per day from the first day of the cycle for 5 days</description>
    <arm_group_label>Ibuprofen</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Women have menorrhagia secondary to IUD.&#xD;
&#xD;
          2. Planning for birth spacing for at least 1 year.&#xD;
&#xD;
          3. Patient aged between 20-45 years old.&#xD;
&#xD;
          4. No history of any medical treatment.&#xD;
&#xD;
          5. Living in a nearby area to make follow-up reasonably possible.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Evidence of defective coagulation.&#xD;
&#xD;
          2. History or evidence of malignancy.&#xD;
&#xD;
          3. Hyperplasia in the endometrial biopsy.&#xD;
&#xD;
          4. Incidental adnexal abnormality on ultrasound.&#xD;
&#xD;
          5. Untreated abnormal cervical cytology&#xD;
&#xD;
          6. contraindications to ibuprofen&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Assiut university</name>
      <address>
        <city>Assiut</city>
        <zip>71111</zip>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2017</verification_date>
  <study_first_submitted>October 18, 2015</study_first_submitted>
  <study_first_submitted_qc>October 18, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 20, 2015</study_first_posted>
  <last_update_submitted>March 20, 2017</last_update_submitted>
  <last_update_submitted_qc>March 20, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">March 21, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Mohammed Khairy Ali</investigator_full_name>
    <investigator_title>Dr</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hemorrhage</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ibuprofen</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

